Rethinking atherogenic risk: is apolipoprotein B a better biomarker?

While the conventional lipid panel remains central to the diagnosis and management of dyslipidemia, accumulating evidence supports the clinical significance of ApoB as a marker of atherogenic risk. Nonetheless, transition toward ApoB-centered strategies requires further validation through adequately powered randomized clinical trials, prospective intervention studies, and real-world implementation analyses demonstrating that ApoB-guided therapy improves clinical outcomes and cost-effectiveness compared with current lipid targets. Such evidence will be essential to definitively establish ApoB not only as a superior risk marker, but also as a primary therapeutic target in cardiovascular prevention.